Northern Trust
CSTL icon

Northern Trust’s Castle Biosciences CSTL Stock Holding History

Northern Trust’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.8M Buy
285,158
+12,057
+4% +$269K ﹤0.01% 2436
2026
Q1 		$6.7M Buy
273,101
+10,858
+4% +$356K ﹤0.01% 2307
2025
Q4 		$10.2M Sell
262,243
-20,024
-7% -$646K ﹤0.01% 2074
2025
Q3 		$6.43M Buy
282,267
+2,442
+0.9% +$49.6K ﹤0.01% 2359
2025
Q2 		$5.71M Buy
279,825
+6,356
+2% +$118K ﹤0.01% 2394
2025
Q1 		$5.47M Sell
273,469
-11,118
-4% -$275K ﹤0.01% 2372
2024
Q4 		$7.58M Buy
284,587
+22,657
+9% +$690K ﹤0.01% 2282
2024
Q3 		$7.47M Buy
261,930
+23,439
+10% +$597K ﹤0.01% 2239
2024
Q2 		$5.19M Sell
238,491
-5,897
-2% -$131K ﹤0.01% 2371
2024
Q1 		$5.41M Sell
244,388
-5,595
-2% -$122K ﹤0.01% 2396
2023
Q4 		$5.39M Buy
249,983
+6,137
+3% +$108K ﹤0.01% 2459
2023
Q3 		$4.12M Buy
243,846
+6,762
+3% +$118K ﹤0.01% 2559
2023
Q2 		$3.25M Buy
237,084
+11,382
+5% +$231K ﹤0.01% 2735
2023
Q1 		$5.13M Sell
225,702
-4,391
-2% -$107K ﹤0.01% 2458
2022
Q4 		$5.42M Buy
230,093
+2,625
+1% +$60.9K ﹤0.01% 2434
2022
Q3 		$5.93M Buy
227,468
+5,337
+2% +$150K ﹤0.01% 2362
2022
Q2 		$4.88M Buy
222,131
+9,806
+5% +$228K ﹤0.01% 2532
2022
Q1 		$9.53M Sell
212,325
-6,337
-3% -$262K ﹤0.01% 2169
2021
Q4 		$9.37M Sell
218,662
-4,933
-2% -$258K ﹤0.01% 2272
2021
Q3 		$14.9M Buy
223,595
+792
+0.4% +$55.7K ﹤0.01% 2003
2021
Q2 		$16.3M Buy
222,803
+45,829
+26% +$3.03M ﹤0.01% 2033
2021
Q1 		$12.1M Buy
176,974
+14,552
+9% +$1.09M ﹤0.01% 2175
2020
Q4 		$10.9M Buy
162,422
+8,117
+5% +$440K ﹤0.01% 2195
2020
Q3 		$7.94M Buy
154,305
+24,670
+19% +$1.1M ﹤0.01% 2250
2020
Q2 		$4.89M Buy
129,635
+21,593
+20% +$738K ﹤0.01% 2540
2020
Q1 		$3.22M Buy
108,042
+51,558
+91% +$1.56M ﹤0.01% 2569
2019
Q4 		$1.94M Buy
56,484
+5,287
+10% +$129K ﹤0.01% 3146
2019
Q3 		$926K Buy
+51,197
New +$1.14M ﹤0.01% 3413

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust's CSTL Position: Q2 2026 in Review

Northern Trust increased its Castle Biosciences (CSTL) stake by 4.4% in Q2 2026, buying an estimated $269K and bringing the position to 285,158 shares worth $6.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

Northern Trust first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $16.3M in Q2 2021. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Northern Trust held 285,158 shares of Castle Biosciences worth $6.8M as of Q2 2026.
  • Northern Trust bought 12,057 Castle Biosciences shares in Q2 2026, an estimated $269K.
  • Castle Biosciences made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2436 holding.
  • Northern Trust first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • Northern Trust's Castle Biosciences position peaked at $16.3M in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.